Navigation Links
Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
Date:4/17/2013

SEATTLE, April 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP‑2) program, for use in the treatment of atypical hemolytic uremic syndrome (aHUS). As Omeros previously announced, based on positive preclinical data in thrombotic microangiopathy (TMA), the first indication planned for OMS721 clinical trials is aHUS, a rare but life-threatening form of TMA. Orphan drug designation is granted to treatments that are expected to provide significant therapeutic advantage over existing treatments and that target conditions affecting 200,000 or fewer U.S. patients per year. Orphan-designated drugs are eligible for incentives such as a faster approval process and additional market exclusivity.

Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein involved in activation of the complement system – an important component of the immune system. The complement system plays a role in the inflammatory response to tissue damage or microbial infection. OMS721 selectively inhibits MASP-2, blocking the lectin pathway of the complement system while leaving intact the classical pathway, which represents the acquired immune response to infection. Soliris® (eculizumab), which received orphan drug status for aHUS and is the only currently approved therapy for that indication, inhibits microbial killing by the classical pathway, increasing the risk of infection for the patient. By targeting only the lectin pathway and leaving the classical pathway intact, OMS721 should not have this increased infection risk. In addition, Soliris requires a
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
2. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
3. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
4. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
5. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
6. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
7. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
8. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
9. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
10. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
11. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/zkkg9q/blood_processing ) has announced the ... Global Strategic Business Report" report to their offering. ... Canada , Japan , ... Latin America , and Rest of World. ... through 2020. Also, a seven-year historic analysis is provided for ...
(Date:6/2/2015)... 2, 2015 The North ... the concerned market with analysis and forecast of ... in 2014, and is estimated to reach $632.5 ... from 2014 to 2019. Browse through ... for an analysis of industry trends and segments, ...
(Date:6/2/2015)... , June 2, 2015 BioDelivery Sciences International, ... conditions, the presentation by Dr. Mark A. Sirgo , ... to 2:30 PM Eastern time. Jefferies 2015 Global ... Grand Hyatt, New York City , NY ... be accessed at www.bdsi.com .  For those who are ...
Breaking Medicine Technology:Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 3North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 3BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference - Schedule Change 2BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference - Schedule Change 3
... VIVUS, Inc. (NASDAQ: VVUS ) today ... accepted for review the company,s new drug application (NDA) for ... dysfunction (ED). The target date for the FDA to complete ... In previously announced results from the pivotal phase 3 trials, ...
... Sept. 1, 2011 Lung Cancer Alliance ... of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) ... on data from two clinical trials, both of which ... Xalkori targets the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma ...
Cached Medicine Technology:VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction 2VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction 3New Drug Approved for Treatment of Non Small Cell Lung Cancer in Specific Patient Population 2
(Date:6/2/2015)... Jersey (PRWEB) June 02, 2015 The ... BCBSNJ) announced today that its Walking and Wellness Challenge, ... Presented by Acer, has raised another $3,000 for the ... Gulbis undertook the challenge, recording 32,000 steps on her ... Stockton Seaview Hotel & Golf Club in Galloway Township. ...
(Date:6/2/2015)... 02, 2015 “ Radaris ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... they need on a person. , According to Psychology Today, ... goes on to explain that curiosity is a part of ...
(Date:6/2/2015)... On October 1, 2015 the transition to ... , On Monday, June 1st Congressman Kevin ... Ways and Means Committee, and 12 members of the ... Medicaid Services, urging the administration to provide a smooth ... ICD-10 is the newest coding system for healthcare professionals ...
(Date:6/2/2015)... Claflin Medical Equipment , a Rhode Island ... RSI Equipment, Inc ., a New York ... With CME’s recent merger of Hospital Associates ... organizations which specialize in the procurement and delivery of ... forces, they now cover the entire country with three ...
(Date:6/2/2015)... Acara Partners has seen a spike in demand for developing ... is now required by recent Google search algorithm changes. ... new clients in the medical aesthetics vertical, are anxious for ... Google’s new requirements,” commented Fran Acunzo, CEO of Acara Partners. ... non-profits, and the business world.” , Back in late ...
Breaking Medicine News(10 mins):Health News:LPGA’s Natalie Gulbis Raises an Additional $3,000 for the Boys & Girls Club of Atlantic City Through Horizon BCBSNJ’s Walking and Wellness Challenge 2Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4Health News:Claflin Medical Equipment (CME) Announces Acquisition of RSI Equipment, Inc. 2Health News:Acara Partners Expands Website and Digital Offerings 2
... National Basketball Association of the US has teamed up with ... kits on HIV/AIDS //to schools in seven provinces of China. ... the kits contain interactive HIV/AIDS learning materials for teachers and ... kit also contains a basketball and other sports equipment to ...
... care services provided to children with special health care ... be below their required need. //In addition, the poorer ... mental health care needs met. These are the two ... Harvard School of Public Health (HSPH) researchers, published in ...
... is generally referred to any factor that affects the physical, ... as we all know, has ramified into various sections of ... ,Although it has been argued that normal levels of ... many. During stress, an important hormone, cortisol, is secreted by ...
... long running disagreement over the funding of the brachytherapy machine ... travel to Christchurch for specialist treatment. ... cervical and other gynecological cancers and was proposed to be ... been ordered because the DHB wants other DHBs to share ...
... According to a study done by Ian Sheerin, lecturer ... of the patients were categorized as avoidable admissions//. The ... could be saved if the condition of the patients ... New Zealand Medical Journal. The largest proportion of avoidable ...
... the effects of alcohol during the drug action week. In ... part of drug action week. ,The role of ... and mental disabilities in children will be stressed during these ... disorders in Kimberley is as high as one in five. ...
Cached Medicine News:Health News:Health Care For Children With Special Needs Compromised 2Health News:Drug Action Week to Highlight Effects of Alcohol 2
IFA for the direct detection of Respiratory Syncytial Virus (RSV)...
BD Directigen RSV Test fast, easy and accurate, its truly STAT. And it will help your laboratory quickly and confidently support critical antiviral therapy recommendations....
Qualitative ELISA for the detection of rotavirus antigen....
Rapid membrane-based immunogold assay for the qualitative detection of rotavirus antigen in human fecal specimens; aids in the diagnosis of acute gastroenteritis caused by rotavirus infection....
Medicine Products: